David Easterday
Family Medicine · Troy, MONPI 1700871613
Payments from drug & device makers
Across 233 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$872
- Supernus Pharmaceuticals, Inc.$795
- Novo Nordisk$421
- Dexcom, Inc.$170
- Pfizer$158
- Vanda Pharmaceuticals Inc.$155
- plus $1K from 30 others
What the payments were for
- Food & beverage$4,01299%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 51 | $872 |
| Supernus Pharmaceuticals, Inc. | 53 | $795 |
| Novo Nordisk | 25 | $421 |
| Dexcom, Inc. | 6 | $170 |
| Pfizer | 10 | $158 |
| Vanda Pharmaceuticals Inc. | 6 | $155 |
| Lilly USA, LLC | 7 | $149 |
| Exact Sciences | 5 | $89 |
| AstraZeneca | 6 | $88 |
| Nestle Healthcare Nutrition Inc. | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 3 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $70 |
| Cranial Technologies, Inc | 3 | $70 |
| Amgen | 4 | $63 |
| Astellas Pharma US Inc | 3 | $61 |
| Boehringer Ingelheim | 3 | $58 |
| Mylan Specialty L.p. | 4 | $53 |
| GSK | 4 | $52 |
| Novartis | 2 | $49 |
| Merck | 3 | $43 |
| Bayer | 2 | $41 |
| Lundbeck LLC | 2 | $41 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| Viatris Specialty LLC | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Abbott | 1 | $25 |
| Nevro Corp. | 1 | $20 |
| Alkermes, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
How this compares
$4,042 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 325 | $211,696 |
| MounjaroTirzepatide | 116 | $138,580 |
| OzempicSemaglutide | 92 | $120,670 |
| VraylarCariprazine Hcl | 71 | $105,407 |
| JardianceEmpagliflozin | 80 | $75,290 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $64,066 |
| XareltoRivaroxaban | 66 | $41,618 |
| TrulicityDulaglutide | 20 | $30,815 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $30,597 |
| FarxigaDapagliflozin Propanediol | 37 | $29,396 |
| JanuviaSitagliptin Phosphate | 38 | $26,960 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,825 |
| WegovySemaglutide | 13 | $23,208 |
| Spiriva RespimatTiotropium Bromide | 26 | $20,543 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $16,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $158 | $216,638342 claims |
| Lilly USA, LLCMounjaro, Trulicity | $149 | $169,396136 claims |
| Novo NordiskOzempic, Wegovy | $421 | $143,878105 claims |
| AbbVieVraylar, Linzess, Restasis | $872 | $118,58797 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $52 | $111,924136 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $58 | $108,271131 claims |
| AstraZenecaFarxiga, Symbicort | $88 | $46,05585 claims |
| MerckJanuvia, Dulera | $43 | $31,63551 claims |
| NovartisEntresto | $49 | $8,64512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Troy
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.